参考文献/References:
[1] Ivanova EA,Bobryshev YV,Orekhov AN. LDL electronegativity index: potential novel index for predicting cardiovascular disease [J]. Vasc Health Risk Manag,2015,11:525-532.
[2] Holinstat M. Normal platelet function [J]. Cancer Metastasis Rev,2017,36(2):195-198.
[3] Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus[J]. Circulation,2016,134(20):1579-1594.
[4] Tourdot BE,Holinstat M. Targeting 12-lipoxygenase as a potential novel antiplatelet therapy[J]. Trends Pharmacol Sci,2017,38(11):1006-1015.
[5] Luci DK,Jameson JB,Yasgar A,et al. Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase[J]. J Med Chem,2014,57(2):495-506.
[6] Adili R,Tourdot BE,Mast K,et al. First selective 12-LOX inhibitor,ML355,impairs thrombus formation and vessel occlusion in vivo with minimal effects on hemostasis[J]. Arterioscler Thromb Vasc Biol,2017,37(10):1828-1839.
[7] Ganbaatar B,Fukuda D,Salim HM,et al. Ticagrelor,a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice[J]. Atherosclerosis,2018,275:124-132.
[8] Franchi F,Rollini F,Angiolillo DJ. Antithrombotic therapy for patients with STEMI undergoing primary PCI [J]. Nat Rev Cardiol,2017,14(6):361-379.
[9] Gremmel T,Yanachkov I,Wright G,et al. Synergistic inhibition of both P2Y1 and P2Y12 adenosine diphosphate receptors as novel approach to rapidly attenuate platelet-mediated thrombosis[J]. Arterioscler Thromb Vasc Biol,2016,36(3):501-509.
[10] Yanachkov IB,Chang H,Yanachkova MI,et al. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors[J]. Eur J Med Chem,2016,107:204-218.
[11] Bertrand OF,Larose E,Bagur R,et al. A randomized double-blind placebo-controlled study comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing transradial rescue percutaneous coronary intervention after failed thrombolysis[J]. Am J Cardiol,2018,122(1):47-53.
[12] Yeung J,Li WJ,Holinstat M. Platelet signaling and disease: targeted therapy for thrombosis and other related diseases[J]. Pharmacol Rev,2018,70(3):526-548.
[13] Xu XR,Wang Y,Adili R,et al. Apolipoprotein A-Ⅳ bindsαⅡbβ3 integrin and inhibits thrombosis[J]. Nat commun,2018,9(1):3608.
[14] Gremmel T,Michelson AD,Frelinger AL,et al. Novel aspects of antiplatelet therapy in cardiovascular disease[J]. Res Pract Thromb Haemost,2018,2(3):439-449.
[15] Ungerer M,Li Z,Baumgartner C,et al. The GPⅥ-Fc fusion protein revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times[J]. PLoS One,2013,8(8):e71193.
[16] Herr AB. Charming the snake: venom-derived peptides show surprising efficacy as glycoprotein Ⅵ-targeting antithrombotic agents[J]. Arterioscler Thromb Vasc Biol,2017,37(7):1266-1268.
[17] Chang CH,Chung CH,Tu YS,et al. Trowaglerix venom polypeptides as a novel antithrombotic agent by targeting immunoglobulin-like domains of glycoprotein Ⅵ in platelet[J].Arterioscler Thromb Vasc Biol,2017,37(7):1307-1314.
[18] Grover SP,Bergmeier W,Mackman N. Platelet signaling pathways and new inhibitors[J]. Arterioscler Thromb Vasc Biol,2018,38(4):e28-e35.
[19] Gurbel PA,Bliden KP,Turner SE,et al. Cell-penetrating pepducin therapy targeting PAR1 in subjects with coronary artery disease[J]. Arterioscler Thromb Vasc Biol,2016,36(1):189-197.
[20] Wong PC,Seiffert D,Bird JE,et al. Blockade of protease-activated receptor- 4(PAR4) provides robust antithrombotic activity with low bleeding[J]. Sci Transl Med,2017,9(371). pii:eaaf5294.
[21] Wilson SJ,Ismat FA,Wang Z,et al. PAR4(protease-activated receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation[J]. Arterioscler Thromb Vasc Biol,2018,38(2):448-456.
[22] Lei X,Reheman A,Hou Y,et al. Anfibatide,a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis[J]. Thromb Haemost,2013,111(2):279-289.
[23] Li TT,Fan ML,Hou SX,et al. A novel snake venom-derived GPIb antagonist, anfibatide,protects mice from acute experimental ischaemic stroke and reperfusion injury[J]. Br J Pharmacol,2015,172(15):3904-3916.
[24] Zheng L,Mao Y,Abdelgawwad MS. Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura[J]. Blood Adv,2016,1(1):75-83.
[25] Huang SW,Kuo HL,Hsu MT,et al. A novel thromboxane receptor antagonist, nstpbp5185,inhibits platelet aggregation and thrombus formation in animal models[J]. Thromb Haemost,2016,116(2):285-299.
[26] Fontana P,Zufferey A,Daali Y,et al. Antiplatelet therapy:targeting the TXA2 pathway[J]. J Cardiovasc Transl Res,2014,7(1):29-38.
[27] Davì G,Santilli F,Vazzana N. Thromboxane receptors antagonists and/or synthase inhibitors[J]. Handb Exp Pharmacol,2012,(210):261-286.
[28] Huang SW,Lien JC,Kuo SC,et al. Inhibitory effects of an orally active thromboxane A2 receptor antagonist,nstpbp5185,on atherosclerosis in apoE-deficient mice[J]. Thromb Haemost,2018,118(2):401-414.
相似文献/References:
[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(5):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(5):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[3]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(5):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[4]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(5):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[5]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[6]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[7]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(5):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[8]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[9]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(5):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
[10]林春尧 刘晓辉.IL-33/ST2在冠心病中的研究进展[J].心血管病学进展,2020,(2):128.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.007]
LIN Chunyao LIU Xiaohui.IL-33/ST2 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(5):128.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.007]